Indication

As a single agent for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

Medicine details

Medicine name:
ibrutinib (Imbruvica)
SMC ID:
SMC2387
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
13 December 2021
SMC meeting date:
02 November 2021
Patient group submission deadline:
06 September 2021